Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:CRMD NASDAQ:MLYS NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$10.25-0.6%$12.39$7.21▼$23.98$2.46B0.835.84 million shs6.50 million shsCRMDCorMedix$7.73-2.2%$7.00$6.13▼$17.43$619.69M1.46947,436 shs846,199 shsMLYSMineralys Therapeutics$29.28-1.2%$27.14$12.59▼$47.65$2.44B0.491.13 million shs826,708 shsRAREUltragenyx Pharmaceutical$25.01+0.8%$22.55$18.29▼$42.37$2.44B0.391.66 million shs1.48 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-3.75%+14.47%-39.95%-55.27%CRMDCorMedix0.00%-0.38%+10.50%-4.06%-16.95%MLYSMineralys Therapeutics0.00%+8.41%+8.49%-7.29%+89.75%RAREUltragenyx Pharmaceutical0.00%+3.25%+10.33%-0.12%-36.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$10.25-0.6%$12.39$7.21▼$23.98$2.46B0.835.84 million shs6.50 million shsCRMDCorMedix$7.73-2.2%$7.00$6.13▼$17.43$619.69M1.46947,436 shs846,199 shsMLYSMineralys Therapeutics$29.28-1.2%$27.14$12.59▼$47.65$2.44B0.491.13 million shs826,708 shsRAREUltragenyx Pharmaceutical$25.01+0.8%$22.55$18.29▼$42.37$2.44B0.391.66 million shs1.48 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-3.75%+14.47%-39.95%-55.27%CRMDCorMedix0.00%-0.38%+10.50%-4.06%-16.95%MLYSMineralys Therapeutics0.00%+8.41%+8.49%-7.29%+89.75%RAREUltragenyx Pharmaceutical0.00%+3.25%+10.33%-0.12%-36.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.83Moderate Buy$25.67150.41% UpsideCRMDCorMedix 2.63Moderate Buy$15.0094.05% UpsideMLYSMineralys Therapeutics 2.67Moderate Buy$49.1467.84% UpsideRAREUltragenyx Pharmaceutical 2.83Moderate Buy$60.76142.96% UpsideCurrent Analyst Ratings BreakdownLatest CRMD, ADMA, MLYS, and RARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026RAREUltragenyx Pharmaceutical BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$44.00 ➝ $43.004/28/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.00 ➝ $14.004/28/2026CRMDCorMedix Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$19.004/28/2026CRMDCorMedix Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.004/27/2026MLYSMineralys Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/27/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/27/2026CRMDCorMedix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $15.004/27/2026CRMDCorMedix D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.004/24/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026MLYSMineralys Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M4.78$0.65 per share15.76$2.01 per share5.10CRMDCorMedix$311.71M1.95$2.00 per share3.86$5.14 per share1.50MLYSMineralys TherapeuticsN/AN/AN/AN/A$8.17 per shareN/ARAREUltragenyx Pharmaceutical$673M3.65N/AN/A($0.83) per share-30.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6017.087.65N/A28.80%37.52%27.87%5/6/2026 (Estimated)CRMDCorMedix$163.05M$2.003.8755.21N/A52.31%52.30%29.46%5/6/2026 (Estimated)MLYSMineralys Therapeutics-$154.65M-$2.37N/AN/AN/AN/A-32.94%-31.68%5/6/2026 (Estimated)RAREUltragenyx Pharmaceutical-$575M-$5.84N/AN/AN/A-85.54%-1,024.42%-43.10%5/5/2026 (Estimated)Latest CRMD, ADMA, MLYS, and RARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026ADMAADMA Biologics$0.1933N/AN/AN/A$139.98 millionN/A5/6/2026Q1 2026CRMDCorMedix$0.35N/AN/AN/A$104.96 millionN/A5/6/2026Q1 2026MLYSMineralys Therapeutics-$0.51N/AN/AN/AN/AN/A5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4968-$1.84-$0.3432$999.00$158.38 millionN/A3/12/2026Q4 2025MLYSMineralys Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/A3/5/2026Q4 2025CRMDCorMedix$0.86$0.16-$0.70$0.16$127.02 million$128.62 million2/25/2026Q4 2025ADMAADMA Biologics$0.20$0.20N/A$0.20$139.80 million$139.16 million2/12/2026Q4 2025RAREUltragenyx Pharmaceutical-$1.20-$1.29-$0.09-$1.29$199.60 million$207.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.166.713.74CRMDCorMedix0.362.111.94MLYSMineralys TherapeuticsN/A43.7643.76RAREUltragenyx PharmaceuticalN/A2.482.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%CRMDCorMedix34.18%MLYSMineralys Therapeutics84.46%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%CRMDCorMedix3.10%MLYSMineralys Therapeutics18.94%RAREUltragenyx Pharmaceutical5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.16 million228.87 millionOptionableCRMDCorMedix3078.44 million76.01 millionOptionableMLYSMineralys Therapeutics2882.45 million66.84 millionOptionableRAREUltragenyx Pharmaceutical1,37198.31 million93.20 millionOptionableCRMD, ADMA, MLYS, and RARE HeadlinesRecent News About These CompaniesUltragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Beats Expectations By $1,000.50 EPS2 hours ago | marketbeat.comUltragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates2 hours ago | zacks.comUltragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates3 hours ago | zacks.comUltragenyx Reports First Quarter 2026 Financial Results and Corporate UpdateMay 5 at 4:01 PM | globenewswire.comUltragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 4,683 SharesMay 4 at 7:25 PM | marketbeat.comAnalysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $61.18May 4 at 6:03 AM | americanbankingnews.comUltragenyx Pharmaceutical (RARE) to Release Quarterly Earnings on TuesdayMay 3 at 4:04 AM | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to Hold at Wall Street ZenMay 3 at 1:05 AM | marketbeat.comPictet Asset Management Holding SA Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RAREMay 1, 2026 | marketbeat.comBarclays Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00April 29, 2026 | marketbeat.comWill Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should KnowApril 29, 2026 | zacks.comUltragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate UpdateApril 29, 2026 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 29, 2026 | marketbeat.comWill Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should KnowApril 28, 2026 | zacks.comUltragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comTeacher Retirement System of Texas Purchases 327,502 Shares of Ultragenyx Pharmaceutical Inc. $RAREApril 26, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Above 50-Day Moving Average - Here's WhyApril 25, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Lowered to Sell Rating by Wall Street ZenApril 25, 2026 | marketbeat.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 24, 2026 | globenewswire.comMassachusetts Financial Services Co. MA Has $7.13 Million Holdings in Ultragenyx Pharmaceutical Inc. $RAREApril 17, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst SaysApril 16, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026Broadcom Hits $2 Trillion Market Cap as Google Reveals New AI ChipsBy Leo Miller | April 28, 2026CRMD, ADMA, MLYS, and RARE Company DescriptionsADMA Biologics NASDAQ:ADMA$10.25 -0.06 (-0.58%) Closing price 04:00 PM EasternExtended Trading$10.30 +0.05 (+0.47%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.CorMedix NASDAQ:CRMD$7.73 -0.17 (-2.15%) Closing price 04:00 PM EasternExtended Trading$7.72 -0.01 (-0.13%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Mineralys Therapeutics NASDAQ:MLYS$29.28 -0.37 (-1.25%) Closing price 04:00 PM EasternExtended Trading$29.28 +0.00 (+0.02%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Ultragenyx Pharmaceutical NASDAQ:RARE$25.01 +0.20 (+0.81%) Closing price 04:00 PM EasternExtended Trading$24.46 -0.55 (-2.18%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
